1,350 results on '"Elkrief A"'
Search Results
152. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study
153. First clinical proof-of-concept that FMT can overcome resistance to ICIs
154. OP-4 DEVELOPMENT AND EXTERNAL VALIDATION OF A MODEL TO PREDICT MULTI-DRUG RESISTANT BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS
155. Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer
156. Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient
157. Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: A retrospective study
158. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma
159. Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness
160. Development and external validation of a model to predict multi-drug resistant bacterial infections in patients with cirrhosis
161. Letter to the Editor: Reply to Zhao, Wu, and Ma
162. Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study
163. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with advanced chronic liver disease: an individual patient meta-analysis
164. Porto sinusoidal vascular liver disorder: natural history and long-term outcome
165. Alpha-1 antitrypsin deficiency is underdiagnosed in cirrhotic liver transplant patients : a retrospective multicenter study
166. Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection-The VALDIG study
167. Current prognosis of gastric variceal bleeding in France: preliminary results from a multicenter prospective cohort of 87 cirrhotic patients
168. Performance of spleen stiffness measurement by vibration-controlled transient elastography to rule out high-risk varices in patients with porto-sinusoidal vascular disorder
169. Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
170. Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
171. Supplementary Table 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
172. Supplementary Figure 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
173. Supplementary Figure 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
174. Supplementary Table 4 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
175. Supplementary Figure 8 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
176. Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
177. Supplementary Table 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
178. Supplementary Table 1 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
179. Supplementary Table 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
180. Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
181. Supplementary Table 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
182. Data from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
183. Supplementary Table 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
184. Supplementary Figure 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
185. Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events
186. Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
187. Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer.
188. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
189. Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
190. Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
191. Data from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
192. Supplementary Table 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
193. Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
194. Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
195. Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification
196. Data from The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
197. Supplementary Figure 1 from The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
198. Supplementary Figure 8 from The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
199. Supplementary Figure 6 from The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
200. Data from A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.